• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Ovide (malathion) 0.5% lotion

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2011


Summary View



  • Chemical burns including second-degree burns

Information for Patients

  • Burns and stinging sensations may occur when using Ovide lotion



  • Other adverse reactions reported… including second-degree burns.
  • It is not known if Ovide Lotion has the potential to cause contact allergic sensitization.